Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Refractory CIDP
NCT03864185Phase 2Completed
- Sponsor
- Nagoya University
- Start
- Mar 2019
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Nagoya University. Started Mar 2019; status: completed.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT03864185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864185.